ACE2 and infection: For SARS-CoV-2 protein-based vaccine candidates, spike proteins and their RBD binding domains are major targets to produce neutralizing antibodies, because they are required for infection by entering, binding, and fusing to angiotensin-converting enzyme 2 (ACE2) on host cells [14].